Abstract：
Is the efficacy of imported vitrified oocyte donation affected by the cryobank of origin?
Longitudinal cohort study, including 249 completed oocyte warming cycles from 200 recipients (January 2016-July 2020). No severe male factor was included. Vitrified oocytes were provided by three Spanish cryobanks. Primary outcome was cumulative live birth delivery rate (CLBR) per completed oocyte warming cycle.
After warming 1535 oocytes, 1244 survived (81.0%) and 945 fertilized (76.0%); embryo utilization rate was 65.3%. The overall CLBR per completed cycle was 47.0% but was lower in cryobank 1 (31.2%) versus cryobank 2 (56.0%, P = 0.0010) and cryobank 3 (50.8%, P = 0.0241). Multivariate logistic regression analysis identified survival of four or more oocytes as the strongest predictor for delivery (P = 0.0282). Only 202 out of 249 oocyte warming cycles had four or more survived oocytes in a proportion that was significantly lower in cryobank 1 versus cryobank 2 (70.1% versus 89.0%, P = 0.0020); comparison with cryobank 3 (81.0%) was not significant. In the 202 oocyte warming cycles, CLBR in cryobank 1 (37.0%) was lower versus cryobank 2 (58.8%, P = 0.0115) and cryobank 3 (60.8%, P = 0.0019), suggesting a reduced viability in oocytes from cryobank 1 that survived warming.
Differences were found in the efficacy of imported vitrified oocytes in relation to the cryobank of origin. Each centre needs to evaluate the results internally when starting a collaboration with an oocyte cryobank to establish the necessary measures to maximize treatment efficacy.
Longitudinal cohort study, including 249 completed oocyte warming cycles from 200 recipients (January 2016-July 2020). No severe male factor was included. Vitrified oocytes were provided by three Spanish cryobanks. Primary outcome was cumulative live birth delivery rate (CLBR) per completed oocyte warming cycle.
After warming 1535 oocytes, 1244 survived (81.0%) and 945 fertilized (76.0%); embryo utilization rate was 65.3%. The overall CLBR per completed cycle was 47.0% but was lower in cryobank 1 (31.2%) versus cryobank 2 (56.0%, P = 0.0010) and cryobank 3 (50.8%, P = 0.0241). Multivariate logistic regression analysis identified survival of four or more oocytes as the strongest predictor for delivery (P = 0.0282). Only 202 out of 249 oocyte warming cycles had four or more survived oocytes in a proportion that was significantly lower in cryobank 1 versus cryobank 2 (70.1% versus 89.0%, P = 0.0020); comparison with cryobank 3 (81.0%) was not significant. In the 202 oocyte warming cycles, CLBR in cryobank 1 (37.0%) was lower versus cryobank 2 (58.8%, P = 0.0115) and cryobank 3 (60.8%, P = 0.0019), suggesting a reduced viability in oocytes from cryobank 1 that survived warming.
Differences were found in the efficacy of imported vitrified oocytes in relation to the cryobank of origin. Each centre needs to evaluate the results internally when starting a collaboration with an oocyte cryobank to establish the necessary measures to maximize treatment efficacy.
摘要：
进口玻璃化卵母细胞捐献的功效是否受到来源冷冻库的影响？
纵向队列研究，包括来自200个受体的249个完成的卵母细胞升温周期（2016年1月至2020年7月）。不包括严重的男性因素。玻璃化卵母细胞由三个西班牙冷冻银行提供。主要结果是每个完成的卵母细胞升温周期的累积活产分娩率（CLBR）。
加温1535个卵母细胞后，1244例存活(81.0%),945例受精(76.0%);胚胎利用率为65.3%。每个完成周期的总CLBR为47.0%，但在冷冻库1(31.2%)中低于冷冻库2(56.0%，P=0.0010)和冷冻库3(50.8%，P=0.0241)。多变量逻辑回归分析确定四个或更多卵母细胞的存活是分娩的最强预测因子(P=0.0282)。在249个卵母细胞升温周期中，只有202个有4个或更多的卵母细胞存活，其比例在冷冻库1中明显低于冷冻库2（70.1％对89.0％，P=0.0020）；与冷冻库3（81.0％）比较无统计学意义。在202个卵母细胞升温周期中，冷冻库1中的CLBR（37.0％）低于冷冻库2中的CLBR（58.8％，P=0.0115)和冷冻库3(60.8%，P=0.0019),这表明来自冷冻库1的卵母细胞存活能力降低。
发现进口的玻璃化卵母细胞相对于来源的冷冻库的功效存在差异。在开始与卵母细胞冷冻库合作时，每个中心都需要在内部评估结果，以建立必要的措施来最大限度地提高治疗效果。
纵向队列研究，包括来自200个受体的249个完成的卵母细胞升温周期（2016年1月至2020年7月）。不包括严重的男性因素。玻璃化卵母细胞由三个西班牙冷冻银行提供。主要结果是每个完成的卵母细胞升温周期的累积活产分娩率（CLBR）。
加温1535个卵母细胞后，1244例存活(81.0%),945例受精(76.0%);胚胎利用率为65.3%。每个完成周期的总CLBR为47.0%，但在冷冻库1(31.2%)中低于冷冻库2(56.0%，P=0.0010)和冷冻库3(50.8%，P=0.0241)。多变量逻辑回归分析确定四个或更多卵母细胞的存活是分娩的最强预测因子(P=0.0282)。在249个卵母细胞升温周期中，只有202个有4个或更多的卵母细胞存活，其比例在冷冻库1中明显低于冷冻库2（70.1％对89.0％，P=0.0020）；与冷冻库3（81.0％）比较无统计学意义。在202个卵母细胞升温周期中，冷冻库1中的CLBR（37.0％）低于冷冻库2中的CLBR（58.8％，P=0.0115)和冷冻库3(60.8%，P=0.0019),这表明来自冷冻库1的卵母细胞存活能力降低。
发现进口的玻璃化卵母细胞相对于来源的冷冻库的功效存在差异。在开始与卵母细胞冷冻库合作时，每个中心都需要在内部评估结果，以建立必要的措施来最大限度地提高治疗效果。
